To evaluate the efficiency of Lantus plus combined oral hypoglycaemic agents in terms of
respondents percentage. The respondent is defined as the person achieving a value in the
final determination of HbA1c < 7% as its absolute value and/or a decreasing in the final
value of HbA1c of more than 12% compared with the initial value (final HbA1c vs. initial
HbA1c).
Describe the glycemia levels and body weight change in the two response groups, (respondents
and non-respondents).
Describe the adverse events Evaluate the safety of using the medication according to the
incidence and relevance of the hypoglycemia events, (symptomatic, diurnal, nocturnal,
severe).
Estimate the intra-patient variability of the fasting glycemia